National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Sacubitril/valsartan (Entresto®)

Entresto® for the treatment of symptomatic chronic heart failure with reduced ejection fraction if adult patients.

Rapid Review

Commenced Completed Outcome
06/11/2015 30/11/2015 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
07/03/2016  08/07/2016 Reimbursement Recommended

The NCPE considers valsartan/sacubitril (Entresto) cost-effective for the current licensed indication and recommends reimbursement.


The HSE has approved reimbursement following confidential price negotiations October 2017.